Perceptive Advisors LLC bought a new position in shares of Contineum Therapeutics, Inc. (NASDAQ:CTNM - Free Report) during the second quarter, according to the company in its most recent disclosure with the SEC. The firm bought 1,566,668 shares of the company's stock, valued at approximately $27,589,000. Perceptive Advisors LLC owned about 6.09% of Contineum Therapeutics as of its most recent SEC filing.
Other large investors also recently bought and sold shares of the company. Driehaus Capital Management LLC acquired a new stake in shares of Contineum Therapeutics during the 2nd quarter worth approximately $1,174,000. Squarepoint Ops LLC acquired a new stake in Contineum Therapeutics in the second quarter worth $2,642,000. Sandia Investment Management LP bought a new stake in Contineum Therapeutics in the second quarter valued at $88,000. Johnson & Johnson bought a new stake in Contineum Therapeutics in the second quarter valued at $34,853,000. Finally, Versant Venture Management LLC acquired a new position in shares of Contineum Therapeutics during the second quarter valued at $16,169,000.
Contineum Therapeutics Stock Performance
Shares of NASDAQ CTNM traded up $0.30 during trading on Monday, hitting $19.14. The company had a trading volume of 48,970 shares, compared to its average volume of 75,256. The firm has a 50-day moving average of $18.73. Contineum Therapeutics, Inc. has a 52 week low of $13.27 and a 52 week high of $22.00.
Contineum Therapeutics (NASDAQ:CTNM - Get Free Report) last released its quarterly earnings results on Tuesday, August 13th. The company reported ($0.39) earnings per share for the quarter, missing analysts' consensus estimates of ($0.37) by ($0.02). On average, research analysts forecast that Contineum Therapeutics, Inc. will post -2.04 earnings per share for the current year.
Wall Street Analysts Forecast Growth
Separately, Royal Bank of Canada upped their price objective on shares of Contineum Therapeutics from $30.00 to $32.00 and gave the stock an "outperform" rating in a report on Wednesday, August 14th.
Get Our Latest Stock Report on CTNM
About Contineum Therapeutics
(
Free Report)
Contineum Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on discovering and developing novel oral small molecule therapies for neuroscience, inflammation, and immunology indications with high unmet need. Its lead asset is PIPE-791, a novel, brain penetrant, small molecule inhibitor of the lysophosphatidic acid 1 receptor (LPA1R) for the treatment of idiopathic pulmonary fibrosis and progressive multiple sclerosis (MS).
See Also
Before you consider Contineum Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Contineum Therapeutics wasn't on the list.
While Contineum Therapeutics currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Click the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
